Department of Physiology & Biophysics, University of Alabama at Birmingham, Birmingham, Alabama 35294
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Hybridomas are fused immortal lymphocytes that typically secrete monoclonal antibodies to a known antigen. Hybridomas express two ionic conductances that have properties consistent with epithelial sodium channel (ENaC) and CFTR. Both ion channels are expressed by lymphocytes. Both of these channels are known to play a role in epithelial cell physiology. However, the physiological role of these channels in lymphocytes is unclear. We tested the hypothesis that ENaC plays a role in the process of regulated antibody secretion. We have been able to demonstrate that hybridomas can be provoked to acutely secrete monoclonal antibodies by a variety of agonists. Concurrently, we were able to show that these same agonists activate amiloride-sensitive sodium currents in whole cell clamped hybridomas. Inhibition of ENaC by amiloride inhibited the acute provoked antibody secretion, thereby linking ENaC to the process of acute antibody secretion. Interestingly, the concentration of amiloride necessary to completely inhibit the provoked secretion was approximately an order of magnitude higher than the concentration necessary to inhibit all of the transmembrane current. However, because amiloride is a weak base, the equilibrium concentration necessary to produce partial inhibition was precisely in accord with the Ki for amiloride and ENaC, indicating that the inhibition was intracellular.
epithelial sodium channel; hybridoma
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE EPITHELIAL SODIUM CHANNEL ENaC is a sodium channel that is inhibited by amiloride (7). One function of this sodium channel is the vectorial transport of sodium across the apical membrane of principal cells located in the collecting duct of the distal renal nephron (11). We have used electrophysiological, biochemical, molecular biological, and immunofluorescent methods to demonstrate directly that ENaC is also expressed by lymphocytes (5). Expression of this sodium channel by lymphocytes has been of considerable assistance in elucidating the basic functional abnormality responsible for Liddle's disease (3). Lymphocytes have also proved useful for the diagnosis of ENaC-induced refractory hypertension (6).
Lymphocyte ENaC is regulated by factors that increase cellular cAMP,
such as norepinephrine (via the 1-adrenergic receptor) (2). Aldosterone also acutely activates human lymphocyte
ENaC (12). The pathway that transduces
aldosterone-mediated ENaC activation utilizes a transmethylation
reaction (12). We have also demonstrated a lymphocyte ENaC
sensitivity to pertussis toxin-mediated ADP-ribosylation of G proteins
(4). These studies of ENaC expressed by human lymphocytes
have provided considerable new knowledge about cellular mechanism that
influence the ion channel function of ENaC. They have not, however,
addressed the question of the physiological function of ENaC in
lymphocytes. Clearly, this sodium channel in peripheral blood
lymphocytes cannot control vectorial salt and water movement as it does
in polarized epithelia. Thus we hypothesized that ENaC may serve some
other cellular function in lymphocytes.
Lymphocytes produce and secrete a variety of inflammatory mediators such as antibodies and cytokines. These products are not secreted in high levels constitutively; rather, they are secreted in response to infection or injury. Thus the secretion of these mediators must be responsive to external signals such as antigen binding or to other inflammatory mediators. Because we had determined previously that ENaC current increased significantly in response to agonists and that ENaC expression in the plasma membrane increased significantly in response to these same agonists (5), we hypothesized that secreted products would increase acutely in response to the same agonists. To test these hypotheses, we measured antibody secretion by hybridomas in response to agonists that increased ENaC current.
Very little is known concerning the precise mechanism whereby immunoglobulins are transported to the plasma membrane and secreted. Immunoferritin cytochemistry on ultrathin frozen sections of normal plasma cells and plasmacytoma cells revealed vacuoles on the trans-side of the Golgi complex containing IgG. It has been speculated that these structures were immunoglobulin secretory vacuoles (8). Another study showed that the polar accumulation of secretory immunoglobulin was contained within vesicles and that the polar multivesiculated structure was responsible for antibody release, either as a free form or packaged within satellite vesicles (10). The specific makeup of the vesicular membrane, specifically the identification of ion channels, has not yet been worked out. However, the structural evidence suggests a vesicular packaging and secretory mechanism for antibody release that is consistent with the experimental findings from the studies described in this report.
Hybridomas synthesize and secrete monoclonal antibodies. These cells must express and utilize proteins and physical mechanisms to carry out this process. The precise details of the mechanisms and the identification of specific proteins involved in carrying out this process have not yet been completely elaborated. One aspect of antibody secretion that seems obvious, but for which there is very little direct evidence, is that, in vivo, plasma cells must have an antibody reserve for the eventuality that antigen-specific cells will encounter their particular antigen. It is also possible that the secretory process responds to stimuli other than antigen binding. For example, catecholamines may play a role in stimulating secretion of cytokines, antibodies, or more catecholamines during an inflammatory reaction. To define this process more precisely and to determine whether ENaC plays a role in the process, we measured monoclonal antibody secretion from hybridomas at 10-min intervals before and after treatment with secretory agonists. We also measured whole cell ENaC currents in hybridomas treated with the same agonists.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasma cell isolation.
Single-cell suspensions were made from the spleens of C57BL6 mice.
Spleen cells were depleted of red blood cells by treatment with an
ammonium chloride-containing buffer. Recovered lymphoid cells were
incubated with a mixture of anti-IgM-FITC (Southern Biotechnology,
Birmingham, AL) and anti-syndecan-1-PE (PharMingen, San Diego, CA). The
treated lymphoid cells were subsequently selected for
IgM+,Syndecanhigh cells by using a MoFlo high-speed
Fluorescent Antibody Cell Sorter (FACS; Cytomation). The recovered
cells were placed in serum-containing medium and stored on ice before
being used for whole cell patch clamp.
Whole cell patch clamp.
Micropipettes were constructed by using a Narashigi pp-83 two-stage
micropipette puller. The tips of these pipettes had an inner diameter
of ~0.3-0.5 µm and an outer diameter of 0.7-0.9 µm.
When filled with an electrolyte solution containing (in mM) 100 K-gluconate, 30 KCl, 10 NaCl, 20 HEPES, 0.5 EGTA, <10 free Ca2+, and 4 ATP at a pH of 7.2, the electrical resistance
of the tip was 1-3 M. The bath solution was serum-free RPMI
1640 cell culture medium (133 mM Na+, 5.3 mM
K+, 108.3 mM Cl
). The solutions approximate
the ionic gradients across the cell membrane in vivo with a Nernst
potential of
83 mV for potassium. Pipettes were mounted in a holder
and connected to the head stage of an Axon 200A patch-clamp amplifier
affixed to a three-dimensional micromanipulator system attached to the
microscope. The pipettes were abutted to the cells, and slight suction
was applied. Seal resistance was continuously monitored (Nicolet model
300 oscilloscope) by using 0.1-mV electrical pulses from an electrical
pulse generator. After formation of seals with resistances in excess of
1 G
, another suction pulse was applied to form the whole cell
configuration by rupturing the membrane within the seal but leaving the
seal intact. Successful completion of this procedure produced a sudden increase in capacitance with no change in seal resistance. The magnitude of the capacitance increase is a direct function of the
membrane available to be voltage clamped (i.e., the membrane area and,
hence, cell size). Typically, this capacitance was between 5-10 pF
for activated peripheral blood lymphocytes. The average capacitances
for collecting duct cells were 11 ± 1.4 (rat) and 9 ± 1.7 pF (rabbit).
Measurement of monoclonal antibody secretion. The hybridoma cells chosen for these experiments (DB9G8, ATCC no. HB124) secreted monoclonal antibodies directed against insulin. Thus the concentration of these monoclonal antibodies was readily measurable by ELISA, using plates coated with insulin. ELISAs were performed to measure the concentration of monoclonal antibodies from a known quantity of cells into a single volume of medium at 10-min intervals for 60 min. To perform this analysis, we filled 96-well Immunlon plates with an insulin solution (1 mg/ml in PBS) and allowed them to incubate for 24 h. After 24 h, the plates were washed and stored for use over 3 days. For the direct ELISA, each well was filled with 100 µl of blocking buffer (PBS supplemented with 10% FBS). Supernatant samples (200 µl) were obtained at each time point and serially diluted. After an incubation period of 2 h at room temperature, the plates were washed three times with 0.05% Tween 20 in PBS. After washing, the wells were filled with 100 µl of blocking buffer and incubated for 10 min at room temperature. After further washing, alkaline phosphatase-conjugated anti-mouse antibodies (1:1,200 dilution in blocking buffer; Jackson ImmunoResearch Labs) were added to the wells (100 µl). The plates were incubated at room temperature for 30 min. After incubation, the plates were washed three times, and 100 µl of p-nitrophenylphosphate was added to develop the reaction. After 10 min of development, the plates were read for the intensity of the reaction by using a Bio-Rad model 550 microplate reader at a wavelength of 405 nm. On each plate, a standard serial dilution was performed by using an initial concentration of 1 µg/ml of commercially available purified anti-insulin monoclonal antibodies (TaKaRa Biomedicals, Otsu, Shiga, Japan). Concentrations from the supernatant were determined by comparison of reaction intensity with that of the known standard. Though each test sample was serially diluted (1:2), for internal control of the concentration measurements, only the concentration determined from the undiluted sample (for each time point) was used for the analysis of the findings. One technical difficulty was that the antibodies used for the standard curves lost potency daily after reconstitution. This technical difficulty did not affect our ability to detect agonist-induced increases in antibody secretion. However, determinations of the absolute concentration of antibodies from day to day and different experimental protocols performed with the use of different standard antibody lots were subject to considerable variability. For this reason, all experiments were performed with internal controls and no conclusions could be drawn concerning the absolute rate of antibody secretion, precluding comparative analysis of some of the experimental findings.
To measure monoclonal antibody secretion, we placed 5-10 million hybridoma cells in a 15-ml conical centrifuge tube. These were washed in RPMI culture medium supplemented with 25% FBS to remove the antibodies secreted when the cells were in culture. The cells were resuspended in 10 ml of RPMI culture medium supplemented with 25% FBS. Initially, a 50-µl sample of the resuspended cells was removed. The cells were stained (trypan blue) and placed in a hemocytometer, and the viable cells were counted. This procedure was repeated for each time point (0, 10, 20, 30, 40, 50, and 60 min). Also, at each time point, a 200-µl sample was removed and the supernatant was stored for ELISA analysis after completion of the full 60 min. The 200-µl samples were not replaced. This procedure potentially introduced a 2% volume concentration increase for each sample. Between time points the cells were allowed to settle without centrifugation so as not to produce artifactual antibody secretion due to excessive handling. The entire sampling process took <30 s for each time point. An additional 5-10 s was required for the addition of agonists as the 20 min time point. For assays in which the effect of agonists was to be tested, the agonists [final concentrations: 40 µM 8-(4-chlorophenylthio)adenosine 3',5'-cyclic monophosphate (CPT-cAMP), 30 µM norepinephrine, or 1.5 µg/ml anti-IgM] were added to the cell suspensions immediately after the 20-min samples were obtained. After each sample, the cells were placed in an incubator at 37°C and allowed to settle. Before each subsequent sample was obtained, the cells were mixed in the suspension by inverting the centrifuge tube three to four times. The entire procedure was then repeated a minimum of six times for unstimulated cells, for each agonist, and for each agonist in the presence of amiloride. For the amiloride trials, RPMI culture medium (25% FBS) was supplemented with the final concentration of amiloride to be tested. The initial cell wash was with amiloride-supplemented RPMI. Thus the cells were continuously exposed to amiloride for the entire procedure, and amiloride was present before the addition of any agonists. All statistical results are presented as means ± SD. Statistical significance was assessed by using Student's t-test. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasma cells and hybridomas have more basal ENaC current than
nonsecreting lymphocytes.
Freshly isolated mouse plasma cells (i.e., antibody-secreting cells)
and transformed murine hybridomas (antibody-secreting cells) were whole
cell patch clamped with the use of normal ionic gradients to determine
whether fusion and transformation induced differences in the
amiloride-sensitive inward sodium currents mediated via ENaC. We found
that the average ENaC currents observed in the transformed hybridomas
(ATCC no. HB124) and the freshly isolated plasma cells were not
significantly different (Fig. 1). ENaC
inward sodium currents were present in both cell types without the need
for agonist stimulation. These findings are in contrast to observations
made in whole cell patch-clamped transformed or freshly isolated human
and murine B lymphocytes (Fig. 1). The only exception to these
observations in nonsecreting B lymphoid cells are lymphocytes derived
from individuals with Liddle's disease (3, 5), which have
constitutively activated basal ENaC currents due to a premature stop
polymorphism of the -subunit.
|
Plasma cell and hybridoma ENaC current is increased by agents that
also provoke antibody secretion.
Antigen binding produces a signal recognized by B lymphocytes and
plasma cells by cross-linking surface IgM. We hypothesized that if ENaC
played a role in antibody secretion, cross-linking surface IgM with
anti-IgM antibodies should increase the amount of ENaC current in
whole cell clamped hybridomas and plasma cells. Figure
2 shows the agonist effect of anti-IgM
antibodies on the inward sodium current in a plasma cell and a
hybridoma. The qualitative and quantitative effects of this treatment
were not different between the cell types. Thus hybridomas appear to
be an appropriate model cell type for investigation of the role
of ENaC in the process of regulated antibody secretion because there
are no differences between freshly isolated plasma cells and hybridomas
with respect to either basal or agonist-stimulated ENaC currents.
|
|
|
Antibody secretion is acutely increased by agents that activate
ENaC current in hybridomas.
Whole cell clamp analysis of hybridoma ENaC current showed that various
agents acutely increased ENaC. We hypothesized that these same agents
could provoke a secretory response by these hybridomas. To test this
hypothesis, we used direct ELISA analysis to measure the change in
concentration of secreted monoclonal antibodies at 10-min intervals.
Between 3 and 5 million cells per assay were washed in fresh culture
medium and resuspended in 10 ml of antibody-free culture medium in
15-ml conical centrifuge tubes. The cells were allowed to settle
without centrifugation and were kept at 37°C in a cell culture
incubator. After 10 min, a sample of the supernatant was taken for
ELISA analysis, the cells were resuspended, and a second sample was
taken for cell counts and viability. This process was repeated every 10 min for 60 min. By following this procedure, a basal secretion rate was established, as shown in Fig. 5A. Figure
5B shows that there was no
change in cell number and viability. Also, there was no change in the
cell number or viability of the cells in any of the experiments in
which the cells were treated with agonists (not shown).
|
|
Amiloride inhibits agonist-induced antibody secretion.
As an additional direct test of the hypothesis that ENaC sodium
channels play a role in agonist-provoked secretion of MAbs, we
determined whether agonist-provoked secretion could be inhibited with
the ENaC-specific inhibitor amiloride. The experimental procedure was
the same as that described earlier. However, the cells were washed in
medium supplemented with amiloride (2, 20, and 100 µM). The amiloride
remained present for the entire sampling procedure. These findings are
shown in Fig. 7. Interestingly, 2 µM
amiloride did not prevent the agonist-provoked increase in secretion
but, rather, delayed the effect by one time point to 40 min instead of
30 min (Fig. 7A). This finding is significant because the
IC50 for amiloride is 75 nM, and a concentration of 2 µM
is more than sufficient to inhibit all of the ENaC current (see Fig.
2). Thus it does not appear as though the plasma membrane ENaC
conductance is necessary for regulated secretion to occur. However, a
concentration of 20 µM amiloride inhibited all of the
agonist-provoked increase in MAb secretion (Fig. 7B), and
100 µM amiloride inhibited all MAb secretion (Fig. 7C).
Because amiloride specifically inhibits ENaC at concentrations of 20 µM and below, it is likely that the delay of secretion at 2 µM and
the complete inhibition of the agonist-provoked secretion at 20 µM
are due to inhibition of ENaC. However, at a concentration of 100 µM,
amiloride may have less specificity. Thus it is not possible to
conclude that at this high concentration, inhibition of ENaC
exclusively by amiloride blocks all MAb secretion by hybridomas. These
findings indicate that the plasma membrane ENaC-mediated plasma
membrane Na+ conductance played no role in regulated
secretion. However, because amiloride did inhibit regulated secretion
at relatively high concentrations, it is possible that inhibition of
ENaC in the membranes of secretory vesicles within the cytoplasm was
the mechanism of inhibition.
|
Uncharged amiloride inhibits agonist-provoked MAb secretion.
Because the inhibition of secretion by amiloride followed the ENaC
inhibition curve with respect to the uncharged amiloride concentration,
the findings suggested that the inhibition of regulated secretion by
amiloride was due to inhibition of ENaC within the cell. To test this
hypothesis further, we altered the uncharged amiloride concentration by
varying the extracellular pH. The pKa of
amiloride is 8.7. Thus amiloride acts as a weak base, and the uncharged
amiloride concentration is determined by the Henderson-Hasselbalch equation. For any concentration of amiloride, the uncharged component will be reduced as the pH is reduced and increased at higher pH values.
For these experiments we used culture medium pH values of 6.6, 7.4, and
8.2. The total amiloride concentration was fixed at 2 µM. Thus the
uncharged (membrane permeant) amiloride concentrations were 16, 100, and 632 nM at the respective pH values. These concentrations span the
amiloride-binding curve, which has an IC50 of ~75 nM. To
ensure that the pH had no independent effect on agonist-stimulated secretion, we performed control experiments without amiloride supplementation. Figure 8 shows the
findings when the pH was elevated to 8.2. There was a qualitative
difference in the findings compared with experiments performed at a pH
of 7.4. The lower absolute concentration of antibodies measured at pH
8.2 may have resulted from differences in standard antibody efficacy or
from differences in the cells secretion rate. The lot-to-lot
differences in efficacy of the anti-insulin MAbs used for the standard
curves performed with each experiment, as well as their tendency to
lose potency within a short time (2 wk), preclude comparisons of
absolute antibody concentration. Thus all experiments were performed
using internal controls. This technical difficulty does not, however,
alter the ability to detect the effects of agonists to activate
antibody secretion and does not alter the conclusions based on these
findings.
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Whole cell patch clamp of plasma cells and hybridomas cells has shown that basal inward sodium current is present in the absence of any stimulation with ENaC agonists. Also, we have shown that cross-linking surface IgM with anti-IgM antibodies increases the ENaC-mediated inward sodium current specifically. Both cell types synthesize and secrete antibodies. These findings are in contrast to whole cell patch-clamp analysis of B lymphoid cells that were not actively synthesizing and secreting antibodies (1-5). This difference led to the hypothesis that ENaC may play a role in the regulated secretion of antibodies. Because regulated secretion must involve the movement of antibody containing vesicles into the plasma membrane, one explanation for the observation of increased ENaC current is that the secretory vesicles sequestering antibodies and containing ENaC in the membrane portion cycle into and out of the plasma membrane to accomplish antibody release. Thus at the instant the cells were whole cell clamped, there was active ENaC in the plasma membrane that would not be present if this process were not taking place. Because no differences in ENaC current (either basal or in response to agonist-mediated activation) were observed between untransformed plasma cells and hybridomas, it appears as though the fusion and transformation used to produce hybridomas did not directly alter the cell physiological process to be examined. Because it is not possible to use plasma cells to perform the secretion measurements necessary to test this hypothesis (because one cannot obtain enough fresh plasma cells that secrete antibodies to a known substrate), hybridomas that secrete MAbs to insulin were chosen to test the hypothesis. Note that the difference in basal ENaC current between antibody-secreting and nonsecreting B lymphoid cells suggested the hypothesis to be tested, but a comparison of ENaC currents between secreting and nonsecreting B lymphoid cells could not in itself provide sufficient information to test the hypothesis.
The secretion assay and the correlated electrophysiological experiments
presented here directly tested the hypothesis that ENaC plays a role in
a specialized lymphocyte secretory function, i.e., secretion in
response to agonist stimulation. This hypothesis was formed to address
the question of the utility of ENaC in lymphocyte function. Previously
we have demonstrated expression of ENaC by normal and polymorphic
lymphocytes (5). We have shown that lymphocyte ENaC is
hyperactive in Liddle's disease (5, 6, 9). We have also
demonstrated activation of lymphocyte ENaC by norepinephrine, via the
1-adrenergic receptor (2). We know that
various signal transduction pathways alter the activity of ENaC in
lymphocytes. For example, ENaC is activated by cAMP (2, 3,
5), modification of G proteins by pertussis toxin activates lymphocyte ENaC (4), and aldosterone acutely activates
human lymphocyte ENaC via a transmethylation reaction
(13). However, none of these previous findings provides an
answer to the question, "What is the physiological function of ENaC
expressed by lymphocytes?"
The physiological function of ENaC is understood in the context of the
regulation of salt balance. ENaC is expressed by renal principal cells
in the distal nephron. The role of ENaC in the kidney is well
understood. The most direct evidence for its role as a regulator of
sodium reabsorption is the excessive salt and water accumulation
associated with Liddle's disease, where there is a proven gain of
function polymorphism in the -subunit of ENaC (12).
Another clear indication of its renal function is the effect of
amiloride. This compound specifically inhibits ENaC and clinically is
used as a potassium-sparing diuretic. Also, amiloride completely
ameliorates hypertension in individuals with hyperactive ENaC
(6).
In lymphocytes, ENaC clearly functions as a sodium channel. However, it is unlikely that lymphocyte ENaC plays a role in salt and water regulation, as it does in renal principal cells. To our knowledge, lymphocytes do not influence the regulation of salt balance in any way. Thus two possibilities are that either the role of ENaC in lymphocyte cell physiology remains to be defined or ENaC plays no role at all in lymphocyte cell physiology. To distinguished between these possibilities, we examined the most obvious (to us) function of lymphocytes. These cells synthesize proteins, such as antibodies and cytokines, for use in mediating inflammatory reactions. We surmised that during an inflammatory reaction to an acute infection, lymphocytes would have to secrete their products very rapidly in a circumscribed area to produce the most efficient reaction in the shortest time. This made sense because bacteria, for example, can multiply at a rapid rate. Thus, to overcome a bacterial infection, the rate of secretion of inflammatory mediators must exceed the rate at which the bacteria multiply. Also, it seemed logical to assume that secretion of these mediators should increase specifically by interaction with antigen or other inflammatory mediators. If this were not the case, the circulation would be inundated with antibodies and cytokines. Using these assumptions and observations, we chose to test directly whether we could alter the rate of monoclonal antibody secretion by hybridoma cells. These cells provide the advantage of secreting large quantities of a single known antibody. This property made it possible to reproducibly measure the rate of secretion at 10-min time intervals by direct ELISA. Figures 4-6 show that the inherent variability of ELISA analysis can be overcome to a degree sufficient to demonstrate significant increases in MAb secretion in response to various chemical stimuli.
Figure 2 shows three stimuli that increase ENaC current in the plasma membrane. These same stimuli acutely increased the rate of antibody secretion (Fig. 5). In fact, these stimuli induced the cells to secrete a pool of preformed antibodies, possibly destined for acute secretion within 10 min, because the secretion rate fell to zero after the single large increase in the rate immediately subsequent to the addition of the agonists. This correlation between currents and the secretory response is suggestive but does not directly implicate ENaC in the process. However, the findings shown in Figs. 6 and 8 directly implicate ENaC in the process, because amiloride inhibits the process.
The ability of amiloride to inhibit regulated secretion partially at 2 µM and completely at 20 µM suggests that the inhibition was intracellular, rather than an inhibition of current at the plasma membrane. The IC50 for amiloride interaction with ENaC is ~75 nM. We have routinely used 2 µM amiloride to completely inhibit ENaC current in lymphocytes in a number of previous studies (1-6). Figure 2 shows the complete inhibition of ENaC current in hybridomas by 2 µM amiloride. Clearly, 2 µM amiloride does not completely inhibit agonist-stimulated secretion (Fig. 6). However, it does delay the effect, as could be expected from a submaximal concentration. The pKa of amiloride is 8.7. Thus, from the Henderson-Hasselbalch equation, the uncharged form of amiloride at pH 7.4 (the pH of the culture medium) is 100 nM. This concentration of amiloride produces a 60% inhibition of ENaC single-channel current in outside-out patches (13). Following the same reasoning, when the medium contained 20 µM amiloride, the uncharged amiloride concentration was 1 µM. This concentration is sufficient to inhibit all ENaC current. Figure 7 shows that 20 µM amiloride prevented the agonist-stimulated MAb secretion.
By varying the pH of the external solution, we were able to use a single concentration of amiloride (2 µM) and alter the inhibition of regulated secretion. Control experiments ruled out the possibility of direct effects of varying the external pH on agonist-stimulated increases in antibody secretion. Additional control experiments using ammonium ions at an equivalent unionized concentration demonstrated that a potential cytoplasmic pH change had no effect on regulated secretion. The remaining possibility was that amiloride inhibited ENaC within the cell. Thus vesicles containing MAbs must have ENaC in their membrane, and this "vesicular" ENaC must play a role in the process of acute antibody secretion that is stimulated by catecholamine or antigen binding. This function may be unique to lymphocytes, or it may also be present in other types of cells that secrete various products in response to external stimuli.
The inhibition of regulated secretion may be due to inhibition of ENaC sodium current across the vesicular membrane or may be due simply to steric interference in a possible binding function of ENaC. Unfortunately, at the present time we are not able to distinguish between these two possible inhibitory mechanisms. It is possible that the Na+ channel function of ENaC is essential for some aspect of the secretory process and that blocking this function on secretory vesicles within the cytoplasm inhibits secretion. It is also possible that ENaC serves as a binding partner for other proteins involved in the movement, fusion, or opening of the secretory vesicles and that when amiloride is bound to ENaC, there is a steric inhibition that prevents a required physical interaction. At present we are not aware of an experiment that would distinguish between these possibilities. Nevertheless, the present observations are consistent with, and support, the hypothesis that ENaC is involved in the specialized process of regulated antibody secretion.
Finally, these observations suggest an immunologic role for ENaC in inflammatory reactions because amiloride can inhibit antibody secretion in vitro. Amiloride is currently used clinically as a potassium-sparing diuretic. Thus the question arises as to whether individuals on amiloride therapy are immunologically compromised. We think this possibility is unlikely because the concentrations of amiloride necessary to inhibit regulated secretion at a physiological pH are well in excess of the therapeutic range of amiloride. At normal serum pH it would take an amiloride concentration in excess of 10 µM to inhibit secretion. This concentration is well above the concentration of amiloride necessary for clinical effectiveness as a potassium-sparing diuretic. Thus it is unlikely that amiloride therapy would have any effect on immune cell function via blockade of ENaC.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. John F. Kearney and Kalaya Attanavanich for the gift of FACS-sorted murine plasma cells.
![]() |
FOOTNOTES |
---|
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK-52789 (J. K. Bubien). J. K. Bubien is an Established Investigator of the American Heart Association.
Address for reprint requests and other correspondence: J. K. Bubien, Dept. of Physiology and Biophysics, 726 McCallum Bldg., Univ. of Alabama at Birmingham, Birmingham, Alabama 35294-0005 (E-mail: bubien{at}uab.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
July 24, 2002;10.1152/ajpcell.00175.2002
Received 16 April 2002; accepted in final form 17 July 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Achard, JM,
Bubien JK,
Benos DJ,
and
Warnock DG.
Stretch modulates amiloride sensitivity and cation selectivity of sodium channels in human B lymphocytes.
Am J Physiol Cell Physiol
270:
C224-C234,
1996
2.
Bubien, JK,
Cornwell T,
Bradford AL,
Fuller CM,
DuVall MD,
and
Benos DJ.
-Adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
Am J Physiol Cell Physiol
275:
C702-C710,
1998[Abstract].
3.
Bubien, JK,
Ismailov II,
Berdiev BK,
Cornwell T,
Lifton RP,
Fuller CM,
Achard JM,
Benos DJ,
and
Warnock DG.
Liddle's disease: abnormal regulation of amiloride-sensitive Na+ channels by -subunit mutation.
Am J Physiol Cell Physiol
270:
C208-C213,
1996
4.
Bubien, JK,
Jope RS,
and
Warnock DJ.
G proteins modulate amiloride-sensitive sodium channels.
J Biol Chem
269:
17780-17783,
1994
5.
Bubien, JK,
Watson B,
Khan MA,
Langloh AL,
Fuller CM,
Berdiev B,
Tousson A,
and
Benos DJ.
Expression and regulation of normal and polymorphic ENaC by human lymphocytes.
J Biol Chem
276:
8557-8566,
2001
6.
Carter, AR,
Zhou ZH,
Calhoun DA,
and
Bubien JK.
Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy.
Am J Physiol Cell Physiol
281:
C1413-C1421,
2001
7.
Garty, H,
and
Benos DJ.
Characteristics and regulatory mechanisms of the amiloride blockable Na+ channel.
Physiol Rev
68:
309-373,
1988
8.
Geuze, HJ,
and
Slot JW.
The subcellular localization of immunoglobulin in mouse plasma cells, as studied with immunoferritin cytochemistry on ultrathin frozen sections.
Am J Anat
158:
161-169,
1980[ISI][Medline].
9.
Ismailov, II,
Berdiev BK,
Fuller CM,
Bradford AL,
Lifton RP,
Warnock DG,
Bubien JK,
and
Benos DJ.
Peptide block of constitutively activated Na+ channels in Liddle's disease.
Am J Physiol Cell Physiol
270:
C214-C223,
1996
10.
Mazzaferro, PK,
Repasky EA,
Black J,
Kubo RT,
and
Bankert RB.
Biochemical and ultrastructural characterization of a novel cell structure associated with immunoglobulin secretion in B-lymphocytes.
J Mol Cell Immunol
3:
293-306,
1987[ISI][Medline].
11.
Schafer, JA,
and
Hawk CT.
Regulation of Na+ channels in the cortical collecting duct by AVP and mineralocorticoids.
Kidney Int
41:
255-268,
1992[ISI][Medline].
12.
Shimkets, RA,
Warnock DG,
Bositis CM,
Nelson-Williams C,
Hansson JH,
Schambelan M,
Gill JR, Jr,
Ulick S,
Milora RV,
Finding JH,
Canessa CM,
Rossier BC,
and
Lifton RP.
Liddle's syndrome: heritable human hypertension caused by mutations of the subunit of the epithelial sodium channel.
Cell
79:
407-414,
1994[ISI][Medline].
13.
Zhou, ZH,
and
Bubien JK.
Nongenomic regulation of ENaC by aldosterone.
Am J Physiol Cell Physiol
281:
C1118-C1130,
2001